Overview of Baralgan-DM

Property	Description
Active Ingredients	Drotaverine, Mefenamic Acid
Form	Oral Tablet
Pharmacological Class	Antispasmodic Agent & Non-Steroidal Anti-inflammatory Drug (NSAID)
Origin	Synthetic
General Purpose	Relief of acute pain characterized by smooth muscle spasm

Definition and Dual Pharmacological Identity

Baralgan-DM is a synthetic fixed-dose combination product formulated as an oral tablet, officially classified as a combination of a potent Antispasmodic Agent and a Non-Steroidal Anti-inflammatory Drug (NSAID).

This structure establishes the medicine as a dual-action entity, designed to address two primary components of painful conditions: the underlying involuntary muscle contractions and the subsequent pain and inflammation they generate. This distinct dual nature provides a comprehensive approach compared to medicinal products containing only a single pharmacological class.

Core Composition and Ingredient Function

The medication contains two distinct active ingredients: Drotaverine and Mefenamic Acid. Drotaverine, a benzylisoquinoline derivative, serves as the antispasmodic component, facilitating the smooth muscle relaxation of visceral tracts, including the gastrointestinal, genitourinary, and biliary systems. Mefenamic Acid, which belongs to the fenamate group of NSAIDs, contributes the analgesic and anti-inflammatory action.

General Therapeutic Purpose and Utility

The primary therapeutic purpose of Baralgan-DM is the effective management of acute visceral pain, particularly discomfort associated with intense, involuntary smooth muscle contractions, typical in conditions like renal or biliary colic. The integrated effect ensures simultaneous relief of the painful cramping (via the antispasmodic action) and the accompanying pain and inflammation (via the NSAID action). This makes the combination a preferred option for pain with a strong spasmodic origin, offering a robust response that extends beyond simple pain modulation.

What side effects are possible with Baralgan-DM?

Possible Side Effects and Safety Information

Baralgan-DM, a combination product containing an antispasmodic (Drotaverine) and a non-steroidal anti-inflammatory drug (NSAID, Mefenamic Acid), carries an official safety profile that includes both common and serious adverse reactions.

Adverse Reaction Categories

Common effects often involve the Gastrointestinal and Nervous Systems, including nausea, vomiting, diarrhea, constipation, dry mouth, heartburn, headache, dizziness, and sleepiness. Allergic reactions such as rashes, itching, and allergic dermatitis are also reported as common.

Classification	Examples of Reactions
Common	Nausea, Vomiting, Diarrhea, Dry Mouth, Dizziness, Headache, Rashes, Hypotension, Tachycardia.
Rare	Serious Allergic Reactions, Agranulocytosis (rare but severe blood disorder associated with the Dipyrone component in related formulations), Blood Clots.

Serious and Clinically Significant Adverse Reactions

Use of the Mefenamic Acid component increases the risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with the duration of use. Additionally, it can cause severe Gastrointestinal (GI) adverse events, such as ulceration, bleeding, and perforation of the stomach or intestine. Severe allergic reactions (e.g., swelling of the face and lips) and potentially fatal skin reactions like Stevens-Johnson Syndrome (SJS) have been documented.

Safety Restrictions and Populations

Contraindications typically include severe heart, liver, or kidney disease; active stomach/intestinal ulcers or bleeding; and a history of a recent heart attack or coronary artery bypass graft (CABG) surgery.
Pregnancy/Lactation: The medicine is generally not recommended for use during pregnancy or breastfeeding, as components may cause potential harm to the fetus or infant.
Other Limitations: Use with caution in the elderly due to increased susceptibility to GI and CV side effects. Caution is advised regarding the concomitant use of alcohol and other medications that increase bleeding risk (e.g., anticoagulants).

Overdose and Emergency Response

An overdose of Baralgan-DM, which combines an antispasmodic and an NSAID, can result in severe systemic toxicity, necessitating immediate emergency action. Documented overdose presentations often include central nervous system effects such as extreme tiredness, confusion, and dizziness. Gastrointestinal distress, including nausea, vomiting, and abdominal pain, is also common.

The official profile lists several potentially life-threatening outcomes. These include severe CNS manifestations like seizures and coma (linked to the NSAID component), and cardiotoxicity (linked to the antispasmodic component) which may cause low blood pressure or severe heart rhythm disturbances. Furthermore, there is a risk of acute renal failure and catastrophic gastrointestinal events, such as bleeding or perforation.

When to Seek Help

Immediate medical attention is mandatory for any suspected overdose, even if symptoms are not yet present. Emergency services must be contacted immediately if the affected person collapses, experiences a seizure, or shows signs of internal bleeding (such as bloody vomit or black, tarry stools). Management is symptomatic and supportive in a hospital setting, and no specific antidote is known. Hospital observation is often required, particularly to monitor for delayed-onset seizures.

Therapeutic Uses of Baralgan-DM

What Baralgan-DM Treats: Main Uses and Benefits

The medication's primary therapeutic focus is on providing supportive relief from pain that involves two specific components: smooth muscle spasm (cramping) and associated inflammation. It is applied in contexts where short-term symptomatic assistance is appropriate for challenging or acute episodes.

Relief of Acute Visceral Colic and Spasms

This combination is commonly used across conditions characterized by severe, involuntary smooth muscle contractions in internal organs. Its components are relevant in areas involving smooth muscle spasm and pain.

The combination is commonly used to help manage symptoms associated with conditions such as renal colic, biliary colic, intestinal cramping, primary dysmenorrhea (painful periods), and spasm-driven muscle pain. Providing simultaneous relief from both the contraction and the pain may contribute to easing the overall symptom load during these acute episodes.

“The dual components are considered relevant in symptomatic management when discomfort is multifaceted, and may assist with maintaining functional stability.”

Quick Fact: Relief for Dual Discomfort The medicine is applied in cases where symptoms cluster into patterns for which supportive management of the spasm/cramping and the accompanying pain/inflammation is considered relevant. It is commonly used when symptoms of acute pain, like those from colic, become disruptive.

Eligibility and Restrictions for Use

Baralgan-DM is intended for use by the standard adult population for the short-term management of acute pain, provided no absolute non-eligibility conditions exist. The regulatory profile, defined by its active ingredients (Drotaverine and Mefenamic Acid, an NSAID), dictates who is eligible and who must not use the medicine.

Absolute Contraindications (Must Not Use)

Individuals are formally contraindicated from using Baralgan-DM if they have a history of hypersensitivity to any of the drug's components or to aspirin/other NSAIDs. Use is also prohibited in patients with severe failure of the heart, kidneys, or liver. Further absolute exclusions include: active peptic ulcers, gastrointestinal bleeding, porphyria, and use during the third trimester of pregnancy.

Populations Requiring Caution or Restricted Use

Age-Related Rules: Use is not recommended in children under 14 years of age, as safety and efficacy have not been established. Use requires specific caution in the elderly (65+ years) due to increased susceptibility to adverse effects.
Physiological Status: Use is not recommended for women who are breastfeeding or those trying to conceive. While pregnant, use is restricted and generally avoided.
Condition-Specific Limits: Patients with mild-to-moderate renal or hepatic impairment and those with uncontrolled hypertension require caution and close monitoring.

What should I know about interactions with other medicines?

This section outlines known and potentially significant interactions associated with Baralgan-DM (Mefenamic Acid and Drotaverine). This information is based on established regulatory drug labeling and medical data.

Potential Drug-Drug and Substance Interactions

The following categories of medicines and substances are noted for interaction potential, primarily based on the actions of the Mefenamic Acid component (a nonsteroidal anti-inflammatory drug or NSAID) and the Drotaverine component:

Other Pain Relievers: Concurrent use with other NSAIDs (e.g., diclofenac, celecoxib) increases the risk of serious gastrointestinal adverse effects, including bleeding and ulceration. The combination is generally not recommended.
Anticoagulants and Antiplatelet Agents: Medicines that thin the blood (e.g., warfarin, clopidogrel) may have their effects enhanced, leading to an increased risk of bleeding. Close monitoring is essential if co-administration is necessary.
Corticosteroids: Combining with corticosteroids (e.g., prednisone) raises the risk of gastrointestinal ulcers and bleeding.
Diabetes Medicines: This product may intensify the blood-glucose-lowering action of certain anti-diabetic medicines (e.g., glibenclamide, glipizide), potentially causing low blood sugar (hypoglycemia).
Diuretics and Blood Pressure Medicines: The effectiveness of diuretics ('water pills,' e.g., furosemide) and certain blood pressure medicines (e.g., captopril) may be reduced. Use of some blood pressure agents, like ACE inhibitors, requires caution.
Immunosuppressants: Co-administration with immunosuppressive agents (e.g., cyclosporine) may increase the risk of kidney damage.
Anti-Parkinson's Medicine: Use with levodopa may result in decreased efficacy of the levodopa, potentially worsening symptoms like rigidity and tremor.

Product-Specific Restriction

Alcohol: Consumption of alcohol must be avoided due to a significantly increased risk of stomach bleeding.

Mechanism of Action

Dual Mechanism: Smooth Muscle and Eicosanoid Modulation

Baralgan-DM engages a complementary dual action on distinct enzyme systems to modulate physiological processes. The first component initiates the selective inhibition of the Phosphodiesterase 4 (PDE4) enzyme within visceral smooth muscle cells. This enzymatic blockade modifies the intracellular cyclic nucleotide pathway, leading to a rise in cAMP concentration that ultimately decreases the Ca^2+ concentration required for smooth muscle contraction. This cascade results in a reduction in smooth muscle tension and contractility across the affected visceral systems.

The second, parallel mechanism involves non-selective inhibition of Cyclooxygenase (COX-1 and COX-2) enzymes. This action disrupts the Arachidonic Acid Cascade, suppressing the synthesis of prostaglandins, which are powerful inflammatory mediators. By limiting the production of these signaling molecules, the mechanism results in lower levels of eicosanoids available to modulate peripheral nociceptor activity, influencing the tissue's sensitivity to chemical signaling.

Dosage and Administration Information

Official Administration Guidelines

Baralgan-DM is a fixed-dose combination product containing Drotaverine 80 mg and Mefenamic Acid 250 mg that is administered via the oral route as a tablet. The administration guidelines establish the standard procedure for intake, frequency, and duration, and this medicine is intended for short-term treatment.

Dosing and Frequency

The standard adult unit dose is one tablet (80 mg/ 250 mg). This dose is typically taken in two to three divided doses over a 24-hour period. The maximum daily intake should not exceed three tablets in total. To ensure proper use, the tablet must be swallowed whole with water and should not be crushed, broken, or chewed.

Timing and Population Constraints

The dose should be taken with or after food. This condition of use is integral to the administration process. Regarding specific populations, the instructions advise using the lowest effective dose for the shortest possible duration in older adults. Use in children under 12 years is generally not established, but adolescents over 12 years may use a modified regimen that stays within the lower daily dose limits for the antispasmodic component.

This structured approach to dosing, frequency, and duration describes how the medicine is utilized.

Recent Clinical Evidence

Baralgan-DM: Recent Clinical Evidence

Clinical research on Baralgan-DM, a combination product containing drotaverine and mefenamic acid, has concentrated on its potential use in managing abdominal pain and cramps associated with conditions such as irritable bowel syndrome (IBS) and dysmenorrhea (painful menstruation).

Clinical Studies on Monotherapy Use

Studies have explored whether drotaverine may act by relaxing smooth muscles in the gastrointestinal tract, while mefenamic acid has been investigated for its potential to affect the release of certain chemical messengers associated with pain sensation. Studies investigated whether this combination may affect pain scores, primarily in patients reporting moderate to severe abdominal discomfort.

Phase II Trials (Dosage and Safety): Early-stage trials assessed initial safety profiles and focused on characterizing common adverse events across different dosage levels.
Phase III Trials (Efficacy Evaluation): Large-scale trials examined the effects of the combined drug compared to a placebo. Primary endpoints involved assessing differences in self-reported pain scores (such as the Visual Analogue Scale, or VAS) over short-term treatment periods.

Combination Therapy Research

Research has also evaluated the use of the drug in relation to specific biological markers.

One study examined whether the combination was associated with changes in inflammation markers (such as C-reactive protein) in a study population over a limited duration. Long-term follow-up research focused on assessing the overall safety profile and the rate of treatment discontinuation due to adverse effects over extended use.

Important Notes from Study Protocols

Absorption: Pharmacokinetic sub-studies have examined the effect of taking the drug with food on its absorption.
Discontinuation: Study protocols have documented the need for monitoring patients if the treatment regimen was modified or discontinued.

How should Baralgan-DM be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory guidelines strictly govern the storage and disposal of Baralgan-DM oral tablets to maintain stability and ensure public safety.

Storage Conditions

Requirement	Specifics Based on Labeling
Temperature	Store below 30 C (or 25 C in some regions).
Container & Protection	Keep in the original, tightly closed container, protected from excess heat, light, and moisture.
Stability	Must be used only before the printed expiry date.

Disposal and Safety Mandates

Regulatory instructions mandate that the medicine must be stored out of the sight and reach of children at all times. When the tablets are expired or no longer required, the product must be appropriately discarded. This disposal process ensures the unused medicine is not consumed by unauthorized individuals or pets, safeguarding against accidental ingestion as documented in official labeling.

Baralgan-DM